Over the past 12 months, $ALNY has been mentioned 13 times across 3 distinct FinTwit voices, with the first mention appearing on August 5, 2025. Adam Feuerstein (@adamfeuerstein) is the dominant voice discussing Alnylam, accounting for 12 of the 13 mentions, while Chris (@itscblast) contributed 2 mentions and シバイヌおやびん (@yasutaketin) contributed 1 mention. The biotech category represents the primary discussion focus for this ticker. Most recent commentary from July 2026 centers on Alnylam's Amvuttra silencer therapy and its competitive positioning within the transthyretin amyloidosis (ATTR) treatment landscape.